ASML vs AXTI

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.

AXTI's deterministic health score is weak, with a Piotroski F-Score of 4/9 indicating borderline financial stability. Despite strong revenue growth of 18.2% and improving earnings trends, the company remains unprofitable with negative margins and ROE, undermining its fundamental strength. Valuation metrics are stretched relative to peers, while insider selling and inconsistent earnings beats suggest caution. However, analyst consensus remains at 'buy' and recent price momentum reflects market optimism about turnaround prospects.